News

Ruconest and Firazyr May Be Viable Options to Treat HAE Attacks During Pregnancy, Study Finds

Ruconest (recombinant C1-inhibitor, rhC1-INH) and Firazyr (icatibant) are safe and effective approaches as first-line treatment for hereditary angioedema (HAE) attacks in pregnant women, a study suggests. Findings of the study, “Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy,” were published in the Journal of…